<DOC>
	<DOCNO>NCT02294682</DOCNO>
	<brief_summary>GSK2140944 demonstrate vitro activity Neisseria ( N. ) gonorrhoeae , include ciprofloxacin resistant susceptible strain . This study Phase II , randomize , multicenter , open-label , dose range study design inform optimal oral dose GSK2140944 characterize efficacy , safety , tolerability subject uncomplicated urogenital gonorrhea due N. gonorrhoeae . Subjects randomly assign receive either single 1500 milligram ( mg ) 3000 mg oral dose GSK2140944 . Appropriate safety microbiological assessment conduct Baseline ( Day 1 ) Visit repeat Test-of-Cure ( Day 4 8 ) Visit . The study duration approximately 1 week . Approximately 60 microbiologically evaluable subject ( 30 subject treatment arm ) complete study arm remain active throughout study .</brief_summary>
	<brief_title>A Dose-Ranging Study Evaluating Efficacy , Safety , Tolerability GSK2140944 Treatment Uncomplicated Urogenital Gonorrhea Caused Neisseria Gonorrhoeae</brief_title>
	<detailed_description />
	<mesh_term>Gonorrhea</mesh_term>
	<criteria>The subject adult male female least 18 year age time sign informed consent meet one follow criterion : 1 . A nonpregnant , nonlactating female childbearing potential 1 ) sexually inactive abstinence , 2 ) sole male partner sterilize , 3 ) use contraceptive method failure rate &lt; 1 % TestofCure Visit . Females childbearing potential must become pregnant study . 2 . A female nonchildbearing potential , include follow : Females surgically sterile document hysterectomy and/or bilateral oophorectomy ; Females document tubal ligation . If procedure do hysteroscopically , effectiveness tubal occlusion must document hysterosalpingogram procedure ( typically 3 month procedure ) ; Females postmenopausal , define amenorrhoeic great 1 year . For woman whose menopausal status doubt , document previous confirmatory blood sample folliclestimulating hormone &gt; 40 milli international unit ( mIU ) /millilitre ( mL ) estradiol &lt; 40 picograms ( pg ) /mL ( &lt; 140 picomoles [ pmol ] /litre [ L ] ) need confirm , require use one acceptable contraception method . Note : For purpose criterion , `` document '' include information obtain via verbal interview subject subject 's medical record . There clinical suspicion subject urogenital gonococcal infection ( e.g. , prior culture , nucleic acid amplification test [ NAAT ] Gram stain presumptive positive presence N. gonorrhoeae , sexual contact partner diagnose gonorrhea within past 14 day , report subject ) . Note : All subject test N. gonorrhoeae , result use determine subject eligibility enrollment study . The subject provide write , date , informed consent willing able comply study protocol . The subject pregnant nursing . The subject hysterectomized female without cervix . The subject male current diagnosis epididymitis orchitis time Baseline Visit . The subject body mass index &gt; =40.0 kilogram ( kg ) /square meter ( m^2 ) . The subject serious underlying disease could imminently life threatening , subject unlikely survive duration study period . The subject medical condition require medication may aggravate inhibition acetylcholinesterase , : Poorly control asthma chronic obstructive pulmonary disease baseline , opinion investigator , stable current therapy ; Acute severe pain , uncontrolled conventional medical management ; Active peptic ulcer disease ; Parkinson 's disease ; Myasthenia gravis ; A history seizure disorder require medication control . This include history childhood febrile seizure ; Any evidence mechanical obstruction urinary digestive track . The subject past history current diagnosis Clostridium difficile infection time Baseline Visit . The subject , judgment investigator , would able willing comply protocol complete study followup . The subject history sensitivity study medication , component thereof , history drug allergy , opinion investigator medical monitor , contraindicate participation . The subject PR interval &lt; 120 &gt; 220 millisecond ( msec ) . Note : Subjects without evaluable PR interval ( e.g. , stable atrial fibrillation ) eligible study . The subject correct QT ( QTc ) &gt; 450 msec QTc &gt; 480 msec subject bundle branch block . Note : The QTc QT interval correct heart rate accord either Bazett formula ( QTcB ) , Fridericia formula ( QTcF ) , machine , manual overread . The subject QRS duration &lt; 70 &gt; 120 msec . The subject preexisting Grade II atrioventricular block high history significant vasovagal and/or syncopal episode episodes symptomatic bradycardia . The subject current chronic history liver disease ( exception Gilbert 's syndrome ) , include symptomatic viral hepatitis moderate severe liver insufficiency ( Child Pugh class B C ) . The subject previously enrol study previously treat GSK2140944 . The subject participate clinical trial receive investigational product within 30 day 5 halflives , whichever longer . The subject follow gonococcal infection : Suspected confirm pelvic inflammatory disease ; Suspected confirm gonococcal arthritis ; Other evidence disseminate gonococcal infection . The subject receive treatment systemic intravaginal antibacterial within 14 day study entry . Subject take medication know risk torsades de pointes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>uncomplicated urogenital gonorrhea</keyword>
	<keyword>Bacterial Type II Topoisomerase Inhibitors ( BTI )</keyword>
	<keyword>antibiotic</keyword>
	<keyword>GSK2140944</keyword>
	<keyword>N. gonorrhoeae</keyword>
</DOC>